Scopus BioPharma(OTC) SCPS

Scopus BioPharma Inc. is a biopharmaceutical company focused on developing innovative treatments for serious diseases, particularly in the field of immuno-oncology. The company is advancing its clinical programs through strategic collaborations with leading organizations.

Products and Services

• Duet Platform featuring CpG signal transducer and STAT3 inhibitors
• MRI-1867, an orally administered dual-action small molecule
• Immuno-oncology gene therapies targeting various cancer forms

Growth Outlook

• Established collaborations with City of Hope and NIH enhance research capabilities
• Focus on immuno-oncology positions the company in a growing market
• Potential for significant advancements in cancer treatment through innovative therapies

Financial Highlights

• Q2 2023 net income of -$2.9 million, reflecting ongoing R&D investments
• Cash and cash equivalents of $362,097 as of June 30, 2023
• Trailing twelve months (TTM) operating cash flow of -$3.9 million

Scopus BioPharma Inc. operates in the biotechnology sector, concentrating on the development of groundbreaking therapies for cancer. The company’s flagship products, including the Duet Platform and MRI-1867, are designed to address significant medical needs in oncology. With a focus on immuno-oncology, Scopus BioPharma is positioned to capitalize on the increasing demand for effective cancer treatments. The growth outlook for Scopus BioPharma is bolstered by strategic partnerships with renowned institutions, which enhance its research capabilities and market presence. The company's commitment to innovation in immuno-oncology places it in a favorable position within a rapidly expanding market. Financially, Scopus BioPharma is in the clinical development phase, with recent quarterly results indicating a net income loss primarily due to substantial research and development expenses. The company reported a cash position of $362,097 as of June 30, 2023, which is critical for sustaining ongoing projects. The trailing twelve months operating cash flow reflects the company's investment in its future growth, despite the current financial challenges. Overall, Scopus BioPharma Inc. presents a compelling opportunity for investors interested in the biotechnology sector, particularly in innovative cancer therapies. The company's strategic focus and partnerships may lead to significant advancements in treatment options for patients facing serious diseases.